The US Food and Drug Administration (FDA) has approved Antares Pharma's (Antares) OTREXUP, a single-dose, disposable auto-injector for the subcutaneous (SC) once-weekly administration of methotrexate (MTX). OTREXUP is reportedly the first ...
Swedish biotechnology firm Karo Bio (KARO) has achieved its first milestone in a research agreement with Pfizer for the development of drugs for treatment of autoimmune diseases. The achievement of milestone in the RORgamma project ...
Can-Fite BioPharma, the parent company of OphthaliX, received a patent entitled ‘Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren’s syndrome’ from the European Patent Office. The ...
Tags: Can-Fite BioPharma
Therapeutic antibodies developer AnaptysBio has expanded its proprietary immunotherapy antibody portfolio to add multiple new combination therapies. The company developed a proprietary anti-PD-1 antibody, called ANB011, with key ...
Tags: AnaptysBio, Antibody Portfolio
Biotechnology company Biocon has launched the first anti-CD6 monoclonal antibody, alzumab (Itolizumab), to treat patients with chronic plaque psoriasis in India. Indicated for the treatment of moderate-to-severe psoriasis, Alzumab is ...
Precision Fabrics Group (PFG), maker of value-added, woven and non-woven technical textiles for performance applications, has selected OEKO-TEX? Standard 100, a comprehensive textile product safety certification program that ensures ...
Tags: Fabrics Group, Fabrics, Textile
FOR IMMEDIATE RELEASE San Carlos, California, United States of America (Free-Press-Release.com) May 9, 2013 -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that ...
Tags: Construction, Decoration
Belgium-based clinical stagebiopharmaceutical company arGEN-X has progressed its fourth therapeutic candidate, ARGX-112, into formal preclinical development. The new human antibody ARGX-112 neutralizes both IL20 and IL22 signaling through ...
Tags: preclinical development, clinical stagebiopharmaceutical, Medicine
The US Food and Drug Administration (FDA) has accepted to review Antares Pharma's new drug application (NDA) of OTREXUP, designed for the treatment of rheumatoid arthritis (RA), poly-articular-course juvenile RA and psoriasis. OTREXUP ...
A "huge loophole" is being carved in the European Union's upcoming data protection regulation, according Ross Anderson, a professor of security engineering at the University of Cambridge in England. The way the current draft of the law ...
Tags: European Union, huge loophole, data protection regulation
Antares Pharma has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Otrexup, a combination product to deliver methotrexate methotrexate (MTX) using Medi-Jet technology. Antares Pharma president ...
Tags: NDA, FDA, medical technology
Stiefel, a GSK company, has acquired the development and commercialization rights to Welichem Biotech (WBI) anti-inflammatory agent, WBI-1001. The acquisition follows the previously announced asset purchase agreement. WBI-1001 ...
Tags: acquisition, clinical drugs, Stiefel
Janssen Biotech has signed a license agreement with Astellas Pharma for the worldwide development and commercialization of ASP015K, except in Japan. Astellas will continue development and commercialization of ASP015K in Japan. ASP015K, ...
Tags: Janssen Biotech, Astellas Pharma, license agreement, ASP015K
LEO Pharma Taclonex (calcipotriene and betamethasone dipropionate) topical suspension, 0.005%/0.064% has won FDA approval for body plaque psoriasis. With the approval, the only once-daily, steroid-containing topical treatment is now ...
Tags: body plaque psoriasis, Medicine
AbGenomics International, a biopharmaceutical company, has obtained FDA agreement on Its Phase 2 clinical trial plans of the novel autoimmune therapeutic candidate, AbGn-168H. The current Phase 2 AbGn-168H trial will be a multicenter, ...
Tags: FDA approval, psoriatic, clinical trial, pharmaceutical product